New drug aims to stop rare blood disorder in its tracks
NCT ID NCT05684159
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase II trial tests a drug called NM8074 in 12 adults with atypical hemolytic uremic syndrome (aHUS), a rare condition that causes blood clots, low platelets, and kidney injury. The drug is given by IV infusion over several weeks. The goal is to see if NM8074 can bring blood counts back to normal and improve kidney function, potentially controlling the disease without the need for ongoing plasma treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NM8074 (a drug given by IV infusion)
- What this could lead to
- If successful, NM8074 could offer a new treatment option to control aHUS, helping patients avoid blood transfusions and kidney damage.
- What could go wrong
- This is a small, early-phase trial with only 12 participants, so results may not apply to everyone. The drug may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AHUS - ATYPICAL HEMOLYTIC UREMIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••